II. Epidemiology
- More common in women than men by 3-7 fold
- Age of onset peaks at 40-60 years
- Increased risk with Family History of autoimmune Thyroid disease
-
Incidence: 0.3 to 1.5 cases per 1000 persons per year (U.S.)
- Most common Autoimmune Disease worldwide
-
Prevalence of Antithyroid Antibody
- Total population: 3-4%
- Euthyroid asymptomatic adolescents: 1.4%
- Middle aged to elderly women: 30-40%
III. Pathophysiology
- Chronic autoimmune Thyroid inflammation
- Thyroid infiltration by Lymphocytes as well as Thyroid fibrosis
- Results in formation of Askanazy cells (Hurthle Cells)
IV. Risk Factors: Hashimoto's with Hypothyroidism
- Excess Iodide intake
- Tobacco Abuse (thiocyanate exposure)
V. Symptoms
- See Hypothyroidism
- May initially experience Hyperthyroidism (rarely, hashitoxicosis)
- Generalized Fatigue
- Weight gain
- Cold intolerance
- Diffuse myalgias
- Painless Thyroiditis (painful in rare cases)
VI. Signs
-
Hypothyroidism
- Rarely Thyrotoxicosis occurs due to the Thyroid Autoantibody stimulating effects
-
Thyroid Goiter (90% of cases)
- Symmetric, diffusely enlarged, non-tender Thyroid
- Firm, irregular Thyroid surface
- Goiter is absent in atrophic form in which fibrosis dominates (with overt Hypothyroidism)
VII. Labs
-
Antithyroid Antibody
-
Antithyroid Microsomal Antibody (Thyroid Peroxidase Antibody or TPO Antibody)
- Present in up to 90-95% of Hashimoto cases (and most specific if significantly elevated)
- More mild elevations of TPO Antibody are seen with other thyroid Autoimmunity
- Antithyroglobulin Antibody are increased in 60-80% of patients
- TSH-receptor blocking Antibody may be present
-
Antithyroid Microsomal Antibody (Thyroid Peroxidase Antibody or TPO Antibody)
-
Thyroid function stepwise change
- First: TSH rises
- Next: T4 declines
- Next: T3 decline
- Last: Symptomatic Hypothyroidism
VIII. Associated conditions
- Pernicious Anemia
- Sjogren's Syndrome
- Chronic hepatitis
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- Adrenal Insufficiency (Addison Disease)
- Type I Diabetes Mellitus
- Vitiligo
- Hepatitis C (untreated)
IX. Management
- TSH >10 mU/L
- Levothyroxine starting at 1.6 mcg/kg/day in young, healthy patients
- Indications for Levothyroxine starting at low dose (12.5 to 25 mcg/day)
- Elderly
- Underlying Coronary Artery Disease
- Tachydysrhythmias
- Recheck Serum TSH every 10-12 weeks
- TSH 4.5 to 10 mU/L
- Pregnancy: Levothyroxine
- See Hypothyroidism in Pregnancy for dosing and monitoring frequency
- Other: Variable recommendations on whether to treat
- Consider treatment for positive TPO Antibody and Hypothyroidism symptoms
- If treated
- Start Levothyroxine 25 to 50 mcg daily
- Recheck Serum TSH in 10-12 weeks
- If not treated
- Recheck Serum TSH for overt Hypothyroidism in 6-12 months
- Pregnancy: Levothyroxine
X. Course
- Initially metabolically normal
- Later Thyroid failure usually ensues
- Thyroid Goiter and symptoms typically resolve by 6 months after becoming euthyroid on replacement
XI. Complications: Thyroid Cancers
- Primary Thyroid Lymphoma (80 fold increased risk)
- Presents as rapidly growing Thyroid Nodule
- FNA Thyroid Nodule
- Papillary Carcinoma